EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals

Yan Huang, Guodong Liang iD, Taoran Wang, Yuheng Ma, Lu Ga, Lijun Sun, Xiao Qi, Wei Zhang, Ruijuan Li, Yan Zhao, Zhao Meng, Xin Gao

Journal of Virology · 2025

DOI: 10.1128/jvi.02289-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Virology, 2025. Verfasst von Yan Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Candidate Medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot,…. Hauptthemen laut MEDLINE: HIV-1, HIV Fusion Inhibitors, Drug Discovery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIDS, caused by HIV-1, is a devastating condition that severely compromises the human immune system, often resulting in fatal consequences. The primary therapeutic approach for AIDS involves a combination of multiple agents, known as “cocktail therapy,” aimed at maximizing and sustainably suppressing viral replication within patients. The ongoing discovery of novel compounds and the establishment of innovative research strategies have become the mandatory path to provide increasingly effective treatment options for AIDS. Peptide-based fusion inhibitors, exemplified as enfuvirtide, are able to target the six-helix bundle fusion core in HIV-1 envelope protein and function during the early stage of viral invasion. However, the prolonged and intensive use of enfuvirtide in clinical settings has posed significant challenges, including the emergence of drug resistance. N-peptide fusion inhibitors, whose sequences are different from enfuvirtide, exhibit potential anti-HIV-1 activity and inhibition of drug-resistant strains through the advanced coiled-coil conformation and are expected to serve as novel peptide inhibitors in the iteration of enfuvirtide. This paper provides a comprehensive summary of N-peptide fusion inhibitor research and development (R&D) to date, with the aim of providing investigators with prospective ideas for exploring antivirals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV Fusion InhibitorsDrug DiscoveryHumansEnfuvirtideHIV Envelope Protein gp41Drug Resistance, ViralHIV InfectionsAntiviral AgentsVirus Replication

Stichwörter der Autor:innen

N-peptide fusion inhibitorantiviralsresearch strategiesvirus

Substanzen

HIV Fusion InhibitorsEnfuvirtideHIV Envelope Protein gp41Antiviral Agents

Autor:innen und Institutionen

  • Key Laboratory for Candidate Medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
  • Beijing Institute of Pharmacology and Toxicology, Beijing, China.

ORCID-Profile: Guodong Liang

Zitieren

APA

Huang, Y., Liang, G., Wang, T., Ma, Y., Ga, L., Sun, L., Qi, X., Zhang, W., Li, R., Zhao, Y., Meng, Z., & Gao, X. (2025). Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals. Journal of Virology. https://doi.org/10.1128/jvi.02289-24

Vancouver

Huang Y, Liang G, Wang T, Ma Y, Ga L, Sun L, et al. Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals. Journal of Virology. 2025. doi:10.1128/jvi.02289-24

BibTeX
@article{Huang2025,
  author = {Huang, Yan and Liang, Guodong and Wang, Taoran and Ma, Yuheng and Ga, Lu and Sun, Lijun and Qi, Xiao and Zhang, Wei and Li, Ruijuan and Zhao, Yan and Meng, Zhao and Gao, Xin},
  title = {Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.02289-24}
}
Kostenlos starten →